GLAND
Gland Pharma Limited (GLAND) Stock Analysis
Gland Pharma Limited is a major Indian injectable pharmaceutical company and CDMO. It manufactures generic injectables and contract development products for global markets. The company is part of the Sanofi group stake structure. It is listed on Indian stock exchanges.
Healthcare › Drug Manufacturers - Specialty & Generic
₹3,061.80
+6.52% 1W | +63.80% 52W
Market Cap
50.5k CR
P/E Ratio
44.7
52W High
₹3171
52W Low
₹1573.6
Div. Yield
0.65%
Beta
0.6
50 DMA
₹2857.9
200 DMA
₹2188.6
Profit Margin
16.8%
Inst. Own.
33.2%
🚀 BREAKOUT
🚀 BREAKOUT
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,209 | 1,373 | 1,545 | 1,537 | 1,402 | 1,406 | 1,384 | 1,425 | 1,506 | 1,487 | 1,695 | 1,743 | 1,800 |
| Expenses | 915 | 1,049 | 1,189 | 1,179 | 1,137 | 1,109 | 1,024 | 1,077 | 1,138 | 1,173 | 1,260 | 1,230 | 1,311 |
| Operating Profit | 294 | 324 | 356 | 359 | 264 | 297 | 360 | 348 | 368 | 314 | 435 | 513 | 489 |
| OPM % | 24% | 24% | 23% | 23% | 19% | 21% | 26% | 24% | 24% | 21% | 26% | 29% | 27% |
| Other Income | 38 | 53 | 37 | 42 | 51 | 60 | 58 | 44 | 58 | 84 | 39 | 111 | 61 |
| Interest | 5 | 6 | 5 | 10 | 6 | 6 | 23 | 7 | 12 | 8 | 4 | 10 | 4 |
| Depreciation | 65 | 81 | 105 | 93 | 92 | 94 | 96 | 96 | 101 | 106 | 108 | 109 | 111 |
| Profit before tax | 261 | 290 | 283 | 298 | 218 | 257 | 299 | 288 | 313 | 284 | 362 | 506 | 435 |
| Tax % | 26% | 33% | 32% | 35% | 34% | 36% | 32% | 35% | 31% | 35% | 28% | 28% | 27% |
| Net Profit | 194 | 194 | 192 | 192 | 144 | 164 | 205 | 187 | 215 | 184 | 261 | 367 | 317 |
| EPS in Rs | 11.79 | 11.78 | 11.65 | 11.68 | 8.73 | 9.93 | 12.42 | 11.32 | 13.08 | 11.15 | 15.87 | 22.26 | 19.21 |
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 2,633 | 3,463 | 4,401 | 3,625 | 5,665 | 5,616 | 6,431 | 6,725 |
| Expenses | 1,678 | 2,161 | 2,890 | 2,600 | 4,332 | 4,348 | 4,801 | 4,974 |
| Operating Profit | 955 | 1,302 | 1,510 | 1,025 | 1,333 | 1,269 | 1,630 | 1,751 |
| OPM % | 36% | 38% | 34% | 28% | 24% | 23% | 25% | 26% |
| Other Income | 139 | 135 | 224 | 184 | 170 | 214 | 292 | 296 |
| Interest | 7 | 3 | 5 | 7 | 26 | 42 | 33 | 26 |
| Depreciation | 95 | 99 | 110 | 147 | 345 | 378 | 424 | 434 |
| Profit before tax | 993 | 1,335 | 1,619 | 1,055 | 1,133 | 1,063 | 1,465 | 1,587 |
| Tax % | 22% | 25% | 25% | 26% | 32% | 34% | 30% | |
| Net Profit | 773 | 997 | 1,212 | 781 | 772 | 699 | 1,027 | 1,129 |
| EPS in Rs | 49.88 | 60.94 | 73.75 | 47.42 | 46.90 | 42.40 | 62.35 | 68.49 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 43% | 42% | 32% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 21.0% | 13.0% | – |
| Profit CAGR | 8.0% | 1.0% | – |
Shareholding Pattern
Promoters51.83%
FIIs7.39%
DIIs32.86%
Public7.93%
Promoters51.83%
FIIs7.90%
DIIs32.63%
Public7.63%
Promoters51.83%
FIIs7.58%
DIIs32.99%
Public7.62%
Promoters51.83%
FIIs7.29%
DIIs33.36%
Public7.52%
Promoters51.77%
FIIs8.74%
DIIs30.44%
Public9.06%
Promoters57.86%
FIIs4.33%
DIIs23.23%
Public14.59%
Promoters57.86%
FIIs3.59%
DIIs25.23%
Public13.32%
Promoters51.83%
FIIs6.90%
DIIs33.27%
Public8.00%
Promoters51.83%
FIIs7.29%
DIIs33.36%
Public7.52%
Promoters51.77%
FIIs8.74%
DIIs30.44%
Public9.06%
GLAND
Holdings Analysis
Key strengths & risk signals
83
Overall
70
Fundamental
97
Technical
Risks (1)
OVERVALUED! PEG of 4.66 means expensive relative to growth rate.
Strengths (4)
GOOD STABILITY! Only 1 revenue dip in history. Strong business fundamentals.
BULLISH TREND! 50-day average (2857.9) is above 200-day average (2188.6) - positive signal.
BREAKOUT! Stock has broken above resistance levels with momentum.
EXCELLENT YEAR! Stock gained 63.8% in the last year.
Fundamental & Technical Analysis
83Overall
70Fundamental
97Technical
Fundamental Breakdown
Growth Quality
23/30
Revenue CAGR: 21.3% (EXCELLENT, 15/15). Profit CAGR: 9.6% (MODERATE, 8/15).
Profit Margin
6/10
GOOD EFFICIENCY! 16.8% profit margin - above average profitability.
PEG Valuation
0/10
OVERVALUED! PEG of 4.66 means expensive relative to growth rate.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0.65% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.03 - excellent financial health.
Public Holding
20/20
VERY LESS PUBLIC HOLDING! 15.97% public ownership - strong promoter/institutional control.
Stability Index
8/10
GOOD STABILITY! Only 1 revenue dip in history. Strong business fundamentals.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (2857.9) is above 200-day average (2188.6) - positive signal.
Price Position
8/10
STRONG POSITION! Current price (3061.8) is above both moving averages.
Trend Pattern
20/20
BREAKOUT! Stock has broken above resistance levels with momentum.
52W Performance
10/10
EXCELLENT YEAR! Stock gained 63.8% in the last year.
Volume Sentiment
30/30
BULLISH SENTIMENT! In last 30 days: 12 up days, 18 down days. Avg volume on up days: 838,430 vs down days: 370,843. Ratio: 2.26x
RSI
3/5
NEUTRAL! RSI at 59.9 - balanced momentum.
52W Range
5/5
STRONG! Trading at 93.2% of 52W range - near yearly highs.
Momentum
4/5
GOOD MOMENTUM! Price has grown across all timeframes - up 6.5% (1 week), 1.2% (1 month), 23.5% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of 0.60 - stable stock, less market risk.
GLAND
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q4FY262026-05-20 | Concall PDF | |
| Q3FY262026-02-03 | Concall PDF | |
| Q2FY262025-11-07 | Concall PDF |
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GLAND | ₹3,061.80 | 44.7 | 16.8% | 21.3% | 9.6% | +63.8% | 83 | BREAKOUT | +47.1% | -13.6% | +19.6% | +3.3% |
| IPCALAB | ₹1,915.40 | 37.1 | 12.9% | 15.5% | 34.3% | +45.3% | 84 | BOUNCE FROM SUPPORT | +72.3% | +34.4% | +20.8% | +16.7% |
| ABBOTINDIA | ₹26,000.00 | 34.2 | 23.1% | 9.0% | 17.8% | -13.4% | 68 | APPROACHING RESISTANCE | +17.1% | +8.5% | +4.3% | +6.1% |
| AJANTPHARM | ₹3,410.10 | 37.6 | 19.6% | 13.4% | 21.6% | +41.1% | 76 | BREAKDOWN | +30.9% | +25.3% | +24.8% | +14.4% |
| ALKEM | ₹5,279.00 | 29.3 | 14.3% | 8.3% | 32.7% | -1.9% | 68 | HIT RESISTANCE | -21.7% | +119.9% | +10.9% | +3.8% |
| GLENMARK | ₹2,293.00 | 34.6 | 10.1% | 13.5% | 66.1% | +17.7% | 69 | BREAKDOWN | +929.6% | +60.2% | +28.5% | +4.6% |
| EMCURE | ₹1,833.50 | 34.4 | 10.4% | 15.4% | 20.2% | +34.8% | 81 | BREAKDOWN | +42.0% | +20.8% | +22.8% | +4.5% |
| WOCKPHARMA | ₹1,996.40 | 79.3 | 11.2% | 7.8% | – | +43.1% | 58 | CONSOLIDATION | -217.8% | -36.1% | +25.9% | -3.7% |
Data from TradeAlone · Updated daily
GLAND News
Gland Pharma Limited (gland) Q1 FY27: Revenues Hit Record High with 20% Y-o-y Growth2026-08-10Gland Pharma Limited (gland) Announces Strategic CDMO Partnership2026-08-09Gland Pharma Limited (gland) Announces Strategic Collaboration with Neuland Laboratories for Sterile API Manufacturing2026-08-05Gland Pharma Limited (gland) Gets Approval for Sugammadex Injection 200 Mg/2 ML2026-07-29Gland Pharma Limited (NSE: GLAND) breaks below support, falls 5%2026-07-22Gland Pharma Limited (GLAND) gains 5% intraday, tests resistance2026-06-30Gland Pharma Limited (gland) Reports Record Revenues and Profitability Consolidated Q4 FY26: 22% Yoy Growth in Revenue and 97% PAT Growth2026-05-15
